In recent years, regulatory bodies, such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have increasingly emphasized the use of real-world data (RWD) in clinical research and regulatory decisions, recognizing its potential to enhance drug development and improve patient outcomes. This shift includes a focus on sourcing RWD that adheres to strict regulatory standards for effective use in drug approvals and postmarket surveillance.
Unlike traditional
Read More
Real World Evidence (RWE)
Guardant Health and ConcertAI Partner to Unlock Cancer Insights with Multi-Modal Real-World Data
What You Should Know:
- Guardant Health, a provider in precision oncology, and ConcertAI, a real-world evidence (RWE) and AI technology company in oncology, announced a strategic collaboration that will provide biopharmaceutical companies with access to a first-of-its-kind multi-modal real-world data (RWD) solution.
- The partnership integrates comprehensive patient electronic medical record (EMR) data with genomic and epigenomic tumor profiling information, offering a deeper
Read More
Optimizing Clinical Trials with AI and Data-Driven Insights
While most technology- and innovation-oriented industries have followed the general principles of Moore’s Law, which holds that computing power would double yearly, while costs were cut in half, the life sciences industry appears to be spending more money developing fewer drugs.
According to the latest data, the cost to take a drug candidate from the discovery stage, all the way to market launch, hit $2.3 billion in 2022—a $298 million rise from 2021. Meanwhile, there were
Read More
Verantos Launches Alzheimer’s Disease Pragmatic Registry to Support RWE Generation
What You Should Know:
- Verantos, the global leader in high-validity real-world evidence at scale, has launched its Alzheimer’s Disease Pragmatic Registry.
- This registry offers life sciences organizations rich and reliable data on patients with Alzheimer’s disease and related conditions.
Verantos: Leading High-Validity Real-World Evidence
Verantos is the global leader in high-validity real-world evidence at scale. By applying artificial intelligence to comprehensive patient
Read More
Atropos Health Raises $33M to Improve Value-Based Care Through Real-World Evidence
What You Should Know:
- Atropos Health, the pioneer in translating real-world clinical data into high-quality personalized real-world evidence for care, today announced a $33 million Series B on the heels of the adoption of its Generative AI platform (GENEVA OSTM) by healthcare institutions, data platforms, research institutions, Life Sciences companies and more.
- The funding was led by Valtruis, with participation from new strategic investors
Read More
Verantos Bolsters Real-World Data Network with 7M Patient Records from CuriMeta
What You Should Know:
- Verantos, the leader in high-quality real-world evidence (RWE) forms a strategic partnership with CuriMeta to expand Verantos' Research Network with de-identified data from 7 million patients,
- The collaboration will enhance the depth and reach of real-world data (RWD) available to life science organizations.
Enhancing RWD Quality and Accessibility
The Verantos Research Network is a unique platform that gathers data from various sources, including academic
Read More
Atropos Health and Google Cloud Partner to Turbocharge Real-World Evidence Generation for Healthcare Systems
What You Should Know:
- Atropos Health, a leader in transforming real-world clinical data into personalized insights, today announced a game-changing collaboration with Google Cloud.
- The partnership optimizes Atropos' GENEVA OS platform to seamlessly integrate with Google Cloud's Healthcare Data Engine (HDE) and BigQuery, empowering healthcare systems to unlock the full potential of their data. By simplifying data access, streamlining analytics, and democratizing insights, this
Read More
Syapse and FDA OCE Collaborate to Advance Real-World Evidence in Oncology
What You Should Know:
- Syapse®, a leading real-world evidence (RWE) company dedicated to extinguishing the fear and burden of serious diseases, and the FDA Oncology Center of Excellence (OCE) today announced the renewal of their four-year collaboration agreement.
- This expanded strategic partnership aims to collaboratively develop and implement research projects that advance the use of real-world data (RWD) and explore the potential of RWE to inform regulatory decisions in
Read More
Inovalon & HealthVerity Partner to Advance Real-World Evidence
What You Should Know:
- Inovalon, a provider of cloud-based software solutions empowering data-driven healthcare, today announced the establishment of a Preferred Data Partner Program.
- The program aims to work with a select number of leading organizations that are committed to the thoughtful application of data towards the improvement of economics and outcomes across the healthcare ecosystem.
HealthVerity Partnership
With the establishment of this program, Inovalon is
Read More
OM1 Launches Asthma and Chronic Rhinosinusitis Datasets to Expand RWE
What You Should Know:
- OM1, a real-world data, AI, and technology company with a focus on chronic diseases launches two new clinical datasets, Chronic Rhinosinusitis (CRS) and Asthma.
- Both datasets are derived from longitudinal follow-ups of patients seen by specialists and focus on patient characteristics, symptoms, treatments, clinical outcomes and healthcare resource utilization. Rapidly growing, the CRS and Asthma datasets each follow approximately 500,000 patients in the U.S.
-
Read More
